Plain-English translation of NCT06248580 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is helping doctors in southeastern Turkey identify and understand hepatitis delta virus (HDV) infection, which is a serious liver virus that can only infect people who already have hepatitis B. Researchers will train local family doctors to recognize HDV and screen 20,000 patients with hepatitis B to see how many also have this riskier infection. The study will also check for liver damage using a safe, non-invasive ultrasound test called fibroscan.
Hepatitis delta virus is particularly dangerous because it causes faster liver damage, cirrhosis, and liver cancer compared to other types of viral hepatitis. Little is known about how common this infection is in southeastern Turkey, so this study exists to find out how many people are affected and to help doctors catch and manage these cases earlier.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have a blood test to check for hepatitis delta virus infection. If your blood test is positive, you will also have a fibroscan, which is a quick, painless ultrasound-like test that checks how much scarring is in your liver. The study does not involve taking any medications — it is purely diagnostic testing to understand your liver health.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Turkey (Türkiye)
Collaborators
SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY, Gilead Sciences
Enrollment target
~20,000 participants
Started
March 2024
Primary completion
February 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yaşar Bayındır, MD
Dicle University, Medical Faculty, Department of Infectious Diseases
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.